David R. Berk

3.4k total citations
109 papers, 1.6k citations indexed

About

David R. Berk is a scholar working on Dermatology, Surgery and Genetics. According to data from OpenAlex, David R. Berk has authored 109 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 46 papers in Dermatology, 21 papers in Surgery and 21 papers in Genetics. Recurrent topics in David R. Berk's work include Dermatology and Skin Diseases (20 papers), Psoriasis: Treatment and Pathogenesis (17 papers) and Genetic and rare skin diseases. (14 papers). David R. Berk is often cited by papers focused on Dermatology and Skin Diseases (20 papers), Psoriasis: Treatment and Pathogenesis (17 papers) and Genetic and rare skin diseases. (14 papers). David R. Berk collaborates with scholars based in United States, Canada and Ireland. David R. Berk's co-authors include Susan J. Bayliss, Anna L. Bruckner, Anne C. Lind, Denise Johnson, Susan M. Swetter, Zsolt Urbán, Helen B. Hubert, James F. Fries, Diane F. Merritt and Susan B. Mallory and has published in prestigious journals such as New England Journal of Medicine, JAMA and The American Journal of Human Genetics.

In The Last Decade

David R. Berk

105 papers receiving 1.5k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
David R. Berk United States 23 562 277 272 260 254 109 1.6k
Yong‐Kwang Tay Singapore 25 797 1.4× 292 1.1× 140 0.5× 227 0.9× 122 0.5× 87 1.8k
S. Raimer United States 22 811 1.4× 330 1.2× 352 1.3× 281 1.1× 178 0.7× 132 2.3k
Miriam Keltz Pomeranz United States 19 422 0.8× 272 1.0× 126 0.5× 225 0.9× 214 0.8× 95 1.4k
Vito Di Lernia Italy 24 915 1.6× 363 1.3× 182 0.7× 191 0.7× 183 0.7× 113 1.7k
Pedro Herranz Spain 23 711 1.3× 442 1.6× 133 0.5× 244 0.9× 123 0.5× 141 1.7k
Agustı́n Alomar Spain 23 855 1.5× 536 1.9× 139 0.5× 232 0.9× 343 1.4× 109 1.8k
Laura Atzori Italy 21 686 1.2× 386 1.4× 112 0.4× 146 0.6× 102 0.4× 136 1.5k
Furen Zhang China 19 369 0.7× 290 1.0× 193 0.7× 157 0.6× 76 0.3× 118 1.5k
J. Toribio Spain 19 482 0.9× 336 1.2× 202 0.7× 102 0.4× 112 0.4× 114 1.1k
V. Descamps France 29 672 1.2× 593 2.1× 212 0.8× 168 0.6× 319 1.3× 165 3.0k

Countries citing papers authored by David R. Berk

Since Specialization
Citations

This map shows the geographic impact of David R. Berk's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David R. Berk with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David R. Berk more than expected).

Fields of papers citing papers by David R. Berk

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David R. Berk. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David R. Berk. The network helps show where David R. Berk may publish in the future.

Co-authorship network of co-authors of David R. Berk

This figure shows the co-authorship network connecting the top 25 collaborators of David R. Berk. A scholar is included among the top collaborators of David R. Berk based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David R. Berk. David R. Berk is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Simpson, Eric L., Lawrence F. Eichenfield, Kim Papp, et al.. (2025). Long-Term Safety and Efficacy with Roflumilast Cream 0.15% in Patients Aged ≥6 Years with Atopic Dermatitis: A Phase 3 Open-Label Extension Trial. Dermatitis. 37(1). 75–83. 1 indexed citations
2.
Simpson, Eric L., Mark Boguniewicz, Lawrence F. Eichenfield, et al.. (2024). 53863 Pooled efficacy, patient-reported outcomes, and safety of roflumilast cream 0.15% from the INTEGUMENT-1 and INTEGUMENT-2 phase 3 clinical trials of adults and children with atopic dermatitis. Journal of the American Academy of Dermatology. 91(3). AB281–AB281.
3.
Draelos, Zoé Kececioglu, et al.. (2024). Assessment of the Vehicle for Roflumilast Cream Compared to a Ceramide-Containing Moisturizing Cream in Mild Eczema. Journal of Drugs in Dermatology. 23(10). 834–840. 2 indexed citations
4.
Simpson, Eric L., Lawrence F. Eichenfield, Melinda Gooderham, et al.. (2023). 390 Efficacy and safety of roflumilast cream 0.15% in adults and children aged ≥6 years with mild to moderate atopic dermatitis in two phase 3 trials (INTEGUMENT-1 and INTEGUMENT-2). British Journal of Dermatology. 188(Supplement_3). 1 indexed citations
5.
Lebwohl, Mark, Linda Stein Gold, Melinda Gooderham, et al.. (2023). Durability of Efficacy and Safety of Roflumilast Cream 0.3% in Adults With Chronic Plaque Psoriasis From a 52-Week, Phase 2 Open-Label Safety Trial. SKIN The Journal of Cutaneous Medicine. 7(2). s111–s111. 1 indexed citations
6.
Gold, Linda Stein, Javier Alonso‐Llamazares, Zoe Draelos, et al.. (2022). Effect of Roflumilast Cream (ARQ-151) on Itch and Itch-Related Sleep Loss in Adults with Chronic Plaque Psoriasis: Patient-Reported Itch Outcomes of a Phase 2b Trial. American Journal of Clinical Dermatology. 24(2). 305–313. 9 indexed citations
7.
Xing, Chao, Mohammed Kanchwala, Jonathan J. Rios, et al.. (2021). Biallelic variants in RNU12 cause CDAGS syndrome. Human Mutation. 42(8). 1042–1052. 9 indexed citations
8.
Berk, David R. & Susan J. Bayliss. (2011). Cellular Phone and Cellular Phone Accessory Dermatitis Due to Nickel Allergy: Report of Five Cases. Pediatric Dermatology. 28(3). 327–331. 13 indexed citations
9.
Nadeau, Kari C., David R. Berk, Geneviève de Saint Basile, et al.. (2011). Genotype, phenotype, and outcomes of nine patients with T‐B+NK+ SCID. Pediatric Transplantation. 15(7). 733–741. 10 indexed citations
10.
Berk, David R. & Susan J. Bayliss. (2010). MRSA, Staphylococcal Scalded Skin Syndrome, and Other Cutaneous Bacterial Emergencies. Pediatric Annals. 39(10). 627–633. 22 indexed citations
11.
Berk, David R., et al.. (2010). Morphologic Features and Natural History of Scalp Nevi in Children. Archives of Dermatology. 146(5). 506–11. 11 indexed citations
12.
Berk, David R. & Alfred T. Lane. (2010). Acquired Bilateral Agminated Spitz Nevi in a Child with Langerhans Cell Histiocytosis. Pediatric Dermatology. 27(3). 282–284. 10 indexed citations
13.
Berk, David R. & Susan J. Bayliss. (2008). Neutrophilic Dermatoses in Children. Pediatric Dermatology. 25(5). 509–519. 25 indexed citations
14.
Berk, David R., et al.. (2008). Sneddon-Wilkinson disease treated with etanercept: report of two cases. Clinical and Experimental Dermatology. 34(3). 347–351. 20 indexed citations
15.
Berk, David R., et al.. (2007). Circumscribed acral hypokeratosis. Journal of the American Academy of Dermatology. 57(2). 292–296. 30 indexed citations
16.
Mallory, Susan B., O Enjolras, Laurence M. Boon, et al.. (2006). Congenital Plaque-Type Glomuvenous Malformations Presenting in Childhood. Archives of Dermatology. 142(7). 892–6. 36 indexed citations
17.
Berk, David R., et al.. (2006). Disease Progression Among HIV-Infected Children Who Receive Perinatal Zidovudine Prophylaxis. JAIDS Journal of Acquired Immune Deficiency Syndromes. 44(1). 106–111. 2 indexed citations
18.
Berk, David R.. (2005). Temporal Trends in Early Clinical Manifestations of Perinatal HIV Infection in a Population-Based Cohort. JAMA. 293(18). 2221–2221. 51 indexed citations
19.
Berk, David R. & Karl G. Sylvester. (2004). Congenital tuberculosis presenting as progressive liver dysfunction. The Pediatric Infectious Disease Journal. 23(1). 78–80. 22 indexed citations
20.
Ruh, Mary F., Yanhua Bi, Linda Cox, et al.. (1998). Effect of Environmental Estrogens on IL-1β Promoter Activity in a Macrophage Cell Line. Endocrine. 9(2). 207–212. 40 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Yong‐Kwang Tay Breakdown of academic impact, for papers by S. Raimer Breakdown of academic impact, for papers by Miriam Keltz Pomeranz Breakdown of academic impact, for papers by Vito Di Lernia Breakdown of academic impact, for papers by Pedro Herranz Breakdown of academic impact, for papers by Agustı́n Alomar Breakdown of academic impact, for papers by Laura Atzori Breakdown of academic impact, for papers by Furen Zhang Breakdown of academic impact, for papers by J. Toribio Breakdown of academic impact, for papers by V. Descamps
Rankless by CCL
2026